Doxazosin-alpha-1-adrenergic antagonists drug in the long-term (3 years). Management of benign prostatic hyperplasia.
To evaluate the efficacy and tolerability of doxazosin in the long-term (3yr.) treatment of bladder outflow obstruction resulting from BPH. Data were obtained in 64 patients with BPH. The main outcome measures were urodynamic and symptomatic evaluation for efficacy. In the three year follow up study on doxazosin, including 33 patients remaining on the drug drug and 11 operated (total 44) and excluding those who abandoned the therapy or died, the positive effect of the treatment was found in 75 percent and failure in 25 percent of cases. Doxazosin was well-tolerated and produced both urodynamic and symptomatic improvement in men with BPH. Results from clinical trials demonstrate doxazosin is effective and safe and well tolerated in both normotensive and hypertensive patients with BPH.
Dutkiewicz
S
S
Department of Urology, Central Clinical Hospital, Warsaw, Poland.
D058668:Adrenergic alpha-1 Receptor Antagonists; D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D000368:Aged; D000369:Aged, 80 and over; D017292:Doxazosin / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011470:Prostatic Hyperplasia / Q000188:drug therapy*; D013997:Time Factors
D058668:Adrenergic alpha-1 Receptor Antagonists; D000317:Adrenergic alpha-Antagonists; D017292:Doxazosin